Henrik Hellborg

1.6k total citations
24 papers, 1.2k citations indexed

About

Henrik Hellborg is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Henrik Hellborg has authored 24 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 8 papers in Cancer Research and 6 papers in Molecular Biology. Recurrent topics in Henrik Hellborg's work include Breast Cancer Treatment Studies (7 papers), Prostate Cancer Treatment and Research (4 papers) and HER2/EGFR in Cancer Research (3 papers). Henrik Hellborg is often cited by papers focused on Breast Cancer Treatment Studies (7 papers), Prostate Cancer Treatment and Research (4 papers) and HER2/EGFR in Cancer Research (3 papers). Henrik Hellborg collaborates with scholars based in Sweden, Denmark and Estonia. Henrik Hellborg's co-authors include Lambert Skoog, Barbro Linderholm, Göran Elmberger, Janne Lehtiö, Unn‐Britt Johansson, Rolf Lewensohn, Jan Adolfsson, Anna L.V. Johansson, Annelie Liljegren and Edoardo Colzani and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Henrik Hellborg

24 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Henrik Hellborg Sweden 18 667 355 337 293 156 24 1.2k
Alfonso Sánchez‐Muñoz Spain 19 537 0.8× 361 1.0× 234 0.7× 186 0.6× 173 1.1× 56 1.0k
Yuka Asano Japan 23 1.0k 1.5× 470 1.3× 278 0.8× 289 1.0× 122 0.8× 111 1.6k
Türkkan Evrensel Türkiye 20 622 0.9× 297 0.8× 274 0.8× 277 0.9× 172 1.1× 95 1.2k
Davide Lombardi Italy 17 609 0.9× 211 0.6× 210 0.6× 308 1.1× 96 0.6× 57 1.0k
Mary Cianfrocca United States 14 869 1.3× 533 1.5× 232 0.7× 239 0.8× 95 0.6× 31 1.3k
Isabel Amendoeira Portugal 15 617 0.9× 449 1.3× 240 0.7× 369 1.3× 191 1.2× 45 1.5k
Amelia Insa Spain 18 1.1k 1.6× 277 0.8× 317 0.9× 697 2.4× 112 0.7× 63 1.5k
Francesco Nuzzo Italy 15 710 1.1× 351 1.0× 229 0.7× 355 1.2× 71 0.5× 48 1.2k
Ninah Achacoso United States 19 456 0.7× 331 0.9× 245 0.7× 158 0.5× 76 0.5× 49 808
Catherine Shannon Australia 20 704 1.1× 285 0.8× 148 0.4× 286 1.0× 191 1.2× 48 1.2k

Countries citing papers authored by Henrik Hellborg

Since Specialization
Citations

This map shows the geographic impact of Henrik Hellborg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Henrik Hellborg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Henrik Hellborg more than expected).

Fields of papers citing papers by Henrik Hellborg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Henrik Hellborg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Henrik Hellborg. The network helps show where Henrik Hellborg may publish in the future.

Co-authorship network of co-authors of Henrik Hellborg

This figure shows the co-authorship network connecting the top 25 collaborators of Henrik Hellborg. A scholar is included among the top collaborators of Henrik Hellborg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Henrik Hellborg. Henrik Hellborg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Peng, Zheng, Lambert Skoog, Henrik Hellborg, et al.. (2014). An expression signature at diagnosis to estimate prostate cancer patients’ overall survival. Prostate Cancer and Prostatic Diseases. 17(1). 81–90. 33 indexed citations
2.
Eriksson, Hanna, Margareta Frohm‐Nilsson, Mari‐Anne Hedblad, et al.. (2013). Interobserver Variability of Histopathological Prognostic Parameters in Cutaneous Malignant Melanoma: Impact on Patient Management. Acta Dermato Venereologica. 93(4). 411–416. 20 indexed citations
3.
Thorstenson, Andreas, Ola Bratt, Olof Akre, et al.. (2012). Incidence of fractures causing hospitalisation in prostate cancer patients: Results from the population-based PCBaSe Sweden. European Journal of Cancer. 48(11). 1672–1681. 30 indexed citations
4.
Gillgren, Peter, Krzysztof T. Drzewiecki, Marianne Niin, et al.. (2011). 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial. The Lancet. 378(9803). 1635–1642. 138 indexed citations
5.
Guðmundsson, Eirikur, et al.. (2011). Metastatic Potential in Renal Cell Carcinomas ≤7cm: Swedish Kidney Cancer Quality Register Data. European Urology. 60(5). 975–982. 83 indexed citations
6.
Arver, Brita, Karin Isaksson, Leif Bergkvist, et al.. (2011). Bilateral Prophylactic Mastectomy in Swedish Women at High Risk of Breast Cancer. Annals of Surgery. 253(6). 1147–1154. 51 indexed citations
7.
Foukakis, Theodoros, Tommy� Fornander, Tobias Lekberg, et al.. (2011). Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden. Breast Cancer Research and Treatment. 130(2). 553–560. 60 indexed citations
8.
Adolfsson, Jan, Andreas Thorstenson, Ola Bratt, et al.. (2011). 1096 ABSOLUTE AND RELATIVE RISK OF FRACTURES IN PROSTATE CANCER PATIENTS: RESULTS FROM THE POPULATION-BASED PCBASE SWEDEN. European Urology Supplements. 10(2). 337–338. 1 indexed citations
9.
Colzani, Edoardo, Annelie Liljegren, Anna L.V. Johansson, et al.. (2011). Prognosis of Patients With Breast Cancer: Causes of Death and Effects of Time Since Diagnosis, Age, and Tumor Characteristics. Journal of Clinical Oncology. 29(30). 4014–4021. 160 indexed citations
10.
Linderholm, Barbro, Henrik Hellborg, Ulla Johansson, Lambert Skoog, & Janne Lehtiö. (2010). Vascular endothelial growth factor receptor 2 and downstream p38 mitogen-activated protein kinase are possible candidate markers of intrinsic resistance to adjuvant endocrine treatment in steroid receptor positive breast cancer. Breast Cancer Research and Treatment. 125(2). 457–465. 19 indexed citations
11.
Segelman, Josefin, Angelique Flöter Rådestad, Henrik Hellborg, Annika Sjövall, & Anna Martling. (2010). Epidemiology and prognosis of ovarian metastases in colorectal cancer. British journal of surgery. 97(11). 1704–1709. 37 indexed citations
12.
Isaksson, Karolin, Brita Arver, Yvonne Brandberg, et al.. (2010). Abstract P6-10-03: Bilateral Prophylactic Mastectomy in Swedish Women at High Risk of Breast Cancer — A National Survey. Cancer Research. 70(24_Supplement). P6–10. 1 indexed citations
13.
al‐Abany, Massoud, Signe Friesland, Henrik Hellborg, et al.. (2009). Esophageal stricture after radiotherapy in patients with head and neck cancer: Experience of a single institution over 2 treatment periods. Head & Neck. 32(4). 452–461. 31 indexed citations
14.
15.
Linderholm, Barbro, Henrik Hellborg, Unn‐Britt Johansson, et al.. (2009). Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Annals of Oncology. 20(10). 1639–1646. 266 indexed citations
16.
Segelman, Josefin, T Singnomklao, Henrik Hellborg, & Anna Martling. (2008). Differences in multidisciplinary team assessment and treatment between patients with stage IV colon and rectal cancer. Colorectal Disease. 11(7). 768–774. 44 indexed citations
17.
Bergqvist, Jenny, John Öhd, Johanna Smeds, et al.. (2007). Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcome. Annals of Oncology. 18(5). 845–850. 31 indexed citations
18.
Dalberg, Kristina, Henrik Hellborg, & Fredrik Wärnberg. (2007). Paget’s disease of the nipple in a population based cohort. Breast Cancer Research and Treatment. 111(2). 313–319. 59 indexed citations
19.
Bergqvist, Jenny, Göran Elmberger, John Öhd, et al.. (2006). Activated ERK1/2 and phosphorylated oestrogen receptor α are associated with improved breast cancer survival in women treated with tamoxifen. European Journal of Cancer. 42(8). 1104–1112. 43 indexed citations
20.
Sharp, Lena, Freddi Lewin, Henrik Hellborg, et al.. (2002). When does my treatment start? – The continuum of care for patients with head and neck cancer. Radiotherapy and Oncology. 63(3). 293–297. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alfonso Sánchez‐Muñoz Breakdown of academic impact, for papers by Yuka Asano Breakdown of academic impact, for papers by Türkkan Evrensel Breakdown of academic impact, for papers by Davide Lombardi Breakdown of academic impact, for papers by Mary Cianfrocca Breakdown of academic impact, for papers by Isabel Amendoeira Breakdown of academic impact, for papers by Amelia Insa Breakdown of academic impact, for papers by Francesco Nuzzo Breakdown of academic impact, for papers by Ninah Achacoso Breakdown of academic impact, for papers by Catherine Shannon
Rankless by CCL
2026